A detailed history of Green Alpha Advisors, LLC transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Green Alpha Advisors, LLC holds 25,598 shares of VERV stock, worth $183,281. This represents 0.1% of its overall portfolio holdings.

Number of Shares
25,598
Previous 19,433 31.72%
Holding current value
$183,281
Previous $94,000 30.85%
% of portfolio
0.1%
Previous 0.08%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 07, 2024

BUY
$4.4 - $7.86 $27,126 - $48,456
6,165 Added 31.72%
25,598 $123,000
Q2 2024

Aug 13, 2024

SELL
$4.76 - $12.79 $26,213 - $70,434
-5,507 Reduced 22.08%
19,433 $94,000
Q1 2024

Apr 09, 2024

BUY
$10.81 - $17.96 $27,824 - $46,229
2,574 Added 11.51%
24,940 $331,000
Q4 2023

Jan 04, 2024

SELL
$8.84 - $18.7 $19,969 - $42,243
-2,259 Reduced 9.17%
22,366 $311,000
Q3 2023

Oct 10, 2023

BUY
$11.42 - $20.82 $281,217 - $512,692
24,625 New
24,625 $326,000

Others Institutions Holding VERV

About Verve Therapeutics, Inc.


  • Ticker VERV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,942,300
  • Market Cap $429M
  • Description
  • Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...
More about VERV
Track This Portfolio

Track Green Alpha Advisors, LLC Portfolio

Follow Green Alpha Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Green Alpha Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Green Alpha Advisors, LLC with notifications on news.